CTOs on the Move

Carrot Fertility

www.get-carrot.com

 
Carrot is a complete global fertility solution for today`s modern employers and payers, providing flexible financial coverage and expert care navigation across the U.S. and 50+ countries. Get a quick demo and briefing about how modern companies are using Carrot to drive down healthcare costs, attract and retain top talent, and build cultures of inclusion.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Jobs

VP, Chief Information Security Officer

Carrot Fertility Remote

Funding

Carrot Fertility raised $24M on 08/18/2020

Similar Companies

Tufts Health Care Institute

Tufts Health Care Institute is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vox Nutrition

We are a supplement manufacturer that specialize in private label supplements & custom supplement formulas. Learn about our manufacuring ablitlies here

Baptist East/Milestone Wellness Ctr.

Fitness classes, lap pool, personal training, weight-loss programs, Pilates, weight training and more. Free mini-membership. All ages and fitness levels welcome.

Sift Healthcare

Founded in 2017, Sift Healthcare is a Milwaukee-based healthcare payments analytics and data science company. Sift`s Payments Intelligence Platform, machine learning integrations and Rev/Track Insights Suite enable healthcare providers and payers to fully leverage their payments data to accelerate insurance reimbursement, improve patient payment strategies and optimize revenue cycle efficiency.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.